Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients

Yonsei Med J. 2008 Jun 30;49(3):429-35. doi: 10.3349/ymj.2008.49.3.429.

Abstract

Purpose: Vascular endothelial growth factor (VEGF) levels in malignant ascites have high diagnostic value for their discrimination from ascites of non-malignant origin. However, there have been no reports on the comparison of VEGF levels between malignant ascites of chemonaive and chemotreated patients.

Materials and methods: VEGF levels were measured in 44 ascites patients (cirrhosis ascites, 10; chemonaive patients, 21; chemotreated patients, 13) and compared to the level of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9). The diagnostic parameters of sensitivity, specificity, and correlation among 3 markers were evaluated.

Results: VEGF levels in malignant ascites of chemonaive and chemotreated patients were significantly higher than those in cirrhotic ascites (p<0.05). VEGF levels in ascites of chemonaive patients were significantly higher than those in chemotreated patients (p<0.05). A cutoff value of 10.4 pg/mL was calculated using receiver operating characteristic curves (ROCs) for VEGF in chemotreated and chemonaive patients, which gave sensitivities of 75.0% and 53.8% and specificities of 69.6% and 47.1%, respectively. Positive correlations were observed between VEGF and CEA (r=0.353, p<0.05) as well as between VEGF and CA19-9 (r=0.367, p<0.05) in ascites.

Conclusion: VEGF levels could be a useful tumor marker for malignant ascites, but its value should carefully be interpreted because of lesser reliability in chemotreated ones.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Ascites / drug therapy*
  • Ascites / metabolism*
  • Ascites / pathology
  • Biomarkers, Tumor / metabolism
  • CA-19-9 Antigen / metabolism
  • Carcinoembryonic Antigen / metabolism
  • Child
  • Female
  • Humans
  • Male
  • Middle Aged
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • Biomarkers, Tumor
  • CA-19-9 Antigen
  • Carcinoembryonic Antigen
  • Vascular Endothelial Growth Factor A